Recombinant
RabMAb

Recombinant Anti-CYP7B1 antibody [EPR8395] - BSA and Azide free (ab248849)

Overview

  • Product name
    Anti-CYP7B1 antibody [EPR8395] - BSA and Azide free
    See all CYP7B1 primary antibodies
  • Description
    Rabbit monoclonal [EPR8395] to CYP7B1 - BSA and Azide free
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human CYP7B1 aa 400-500. The exact sequence is proprietary.

  • General notes

    ab248849 is a PBS-only buffer format of ab138497. Please refer to ab138497 for recommended dilutions, protocols, and image data.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab248849 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Detects a band of approximately 55 kDa (predicted molecular weight: 58 kDa).
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • Tissue specificity
      Brain, testis, ovary, prostate, liver, colon, kidney, and small intestine.
    • Pathway
      Lipid metabolism; bile acid biosynthesis.
    • Involvement in disease
      Defects in CYP7B1 are the cause of spastic paraplegia autosomal recessive type 5A (SPG5A) [MIM:270800]. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.
      Defects in CYP7B1 are the cause of congenital bile acid synthesis defect type 3 (CBAS3) [MIM:613812]. Clinical features include severe cholestasis, cirrhosis and liver synthetic failure. Hepatic microsomal oxysterol 7-alpha-hydroxylase activity is undetectable.
    • Sequence similarities
      Belongs to the cytochrome P450 family.
    • Cellular localization
      Endoplasmic reticulum membrane. Microsome membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • 25 hydroxycholesterol 7 alpha hydroxylase antibody
      • 25-hydroxycholesterol 7-alpha-hydroxylase antibody
      • CP7B antibody
      • CP7B1_HUMAN antibody
      • Cyp7b1 antibody
      • Cytochrome P450 7B1 antibody
      • Cytochrome P450 family 7 subfamily B polypeptide 1 antibody
      • Cytochrome P450 subfamily VIIB polypeptide 1 antibody
      • Oxysterol 7-alpha-hydroxylase antibody
      • Oxysterol 7alpha hydroxylase antibody
      see all

    References

    ab248849 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab248849.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up